In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals
- PMID: 16501974
- DOI: 10.1007/s00259-005-0048-4
In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals
Abstract
Purpose: The application of in vivo bioluminescence imaging to non-invasive, quantitative monitoring of tumour models relies on a positive correlation between the intensity of bioluminescence and the tumour burden. We conducted cell culture studies to investigate the relationship between bioluminescent signal intensity and viable cell numbers in murine leukaemia model cells.
Methods: Interleukin-3 (IL-3)-dependent murine pro-B cell line Ba/F3 was transduced with firefly luciferase to generate cells expressing luciferase stably under the control of a retroviral long terminal repeat. The luciferase-expressing cells were transduced with p190 BCR-ABL to give factor-independent proliferation. The cells were cultured under various conditions, and bioluminescent signal intensity was compared with viable cell numbers and the cell cycle stage.
Results: The Ba/F3 cells showed autonomous growth as well as stable luciferase expression following transduction with both luciferase and p190 BCR-ABL, and in vivo bioluminescence imaging permitted external detection of these cells implanted into mice. The bioluminescence intensities tended to reflect cell proliferation and responses to imatinib in cell culture studies. However, the luminescence per viable cell was influenced by the IL-3 concentration in factor-dependent cells and by the stage of proliferation and imatinib concentration in factor-independent cells, thereby impairing the proportionality between viable cell number and bioluminescent signal intensity. Luminescence per cell tended to vary in association with the fraction of proliferating cells.
Conclusion: Although in vivo bioluminescence imaging would allow non-invasive monitoring of leukaemia model animals, environmental factors and therapeutic interventions may cause some discrepancies between tumour burden and bioluminescence intensity.
Similar articles
-
In vivo bioluminescence imaging of murine xenograft cancer models with a red-shifted thermostable luciferase.Mol Imaging Biol. 2010 Aug;12(4):406-14. doi: 10.1007/s11307-009-0291-3. Epub 2009 Nov 25. Mol Imaging Biol. 2010. PMID: 19937390
-
Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model.Exp Hematol. 2008 Dec;36(12):1634-41. doi: 10.1016/j.exphem.2008.08.004. Epub 2008 Oct 25. Exp Hematol. 2008. PMID: 18951691
-
Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy.Exp Hematol. 2007 Mar;35(3):407-15. doi: 10.1016/j.exphem.2006.11.006. Exp Hematol. 2007. PMID: 17309821
-
Bioluminescent imaging: a critical tool in pre-clinical oncology research.J Pathol. 2010 Feb;220(3):317-27. doi: 10.1002/path.2656. J Pathol. 2010. PMID: 19967724 Review.
-
In vivo bioluminescence imaging.Comp Med. 2004 Dec;54(6):631-4. Comp Med. 2004. PMID: 15679260 Review.
Cited by
-
Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission.J Hematol Oncol. 2013 Jan 23;6:10. doi: 10.1186/1756-8722-6-10. J Hematol Oncol. 2013. PMID: 23343252 Free PMC article.
-
Subcutaneous administration of D-luciferin is an effective alternative to intraperitoneal injection in bioluminescence imaging of xenograft tumors in nude mice.ISRN Mol Imaging. 2013;2013:689279. doi: 10.1155/2013/689279. ISRN Mol Imaging. 2013. PMID: 25392739 Free PMC article.
-
Plasma protein binding of luciferase substrates influences sensitivity and accuracy of bioluminescence imaging.Mol Imaging Biol. 2011 Feb;13(1):59-66. doi: 10.1007/s11307-010-0325-x. Mol Imaging Biol. 2011. PMID: 20383591
-
Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging.Eur J Nucl Med Mol Imaging. 2009 May;36(5):771-9. doi: 10.1007/s00259-008-1022-8. Epub 2008 Dec 19. Eur J Nucl Med Mol Imaging. 2009. PMID: 19096841
-
Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.Cancer Sci. 2011 Nov;102(11):2014-21. doi: 10.1111/j.1349-7006.2011.02039.x. Epub 2011 Sep 1. Cancer Sci. 2011. PMID: 21777350 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous